title: Vasoactive intestinal peptide is an important endocrine regulatory factor of fetal rat testicular steroidogenesis.
abstract: This study elaborates our recent preliminary finding that vasoactive intestinal peptide (VIP) has a specific stimulatory effect on fetal rat Leydig cells. We examined the dose-response relationship for the effect of VIP on cAMP and testosterone production by dispersed fetal Leydig cells isolated from rat testes on embryonic day (E) 18.5. Further, we used RT-PCR to examine the expression of the VIP gene in fetal brain and testes and that of the VIP receptor genes in fetal testes and used RIA to measure VIP in testes and plasma during the fetal period. VIP stimulated fetal testicular cAMP production at a dose of 10(-9) mol/liter, whereas a dose as low as 10(-12) mol/liter stimulated testosterone production. This suggests that VIP at low doses may stimulate testosterone production using second messenger pathways other than cAMP. RT-PCR analysis could not reveal either VIP messenger RNA (mRNA) in fetal tissues or VIP1 receptor mRNA in the fetal or newborn testes, whereas VIP2 receptor mRNA was detected in fetal testes as early as E15.5. Northern hybridization analysis showed that the level of expression of VIP2 receptor mRNA is very low in fetal and neonatal testes and increases with age. The testicular VIP content was unmeasurable by our RIA method (i.e. <1 fmol/testis), whereas the circulating level of VIP was 82.9 +/- 1.1 pmol/liter on E17.5 and decreased with advancing fetal age. In conclusion, our results suggest that VIP from an extratesticular source, possibly from the maternal compartment, may regulate fetal testicular steroidogenesis through type 2 receptors as early as E15.5. These findings may be of physiological significance, because the onset of fetal testicular steroidogenesis occurs at an age (E15.5-19.5) before the onset of pituitary LH secretion.
authors.affiliation: Department of Physiology, University of Turku, Finland.
authors.forename: F
authors.initials: F
authors.lastname: El-Gehani
authors.forename: M
authors.initials: M
authors.lastname: Tena-Sempere
authors.forename: I
authors.initials: I
authors.lastname: Huhtaniemi
mesh_terms: D000818:Animals; D015152:Blotting, Northern; D015139:Blotting, Southern; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000096:biosynthesis; D005260:Female; D015870:Gene Expression; D007985:Leydig Cells / Q000187:drug effects / Q000378:metabolism; D008297:Male; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018005:Receptors, Vasoactive Intestinal Peptide / Q000235:genetics; D051239:Receptors, Vasoactive Intestinal Peptide, Type II; D015290:Second Messenger Systems; D013737:Testis / Q000187:drug effects / Q000196:embryology* / Q000378:metabolism*; D013739:Testosterone / Q000096:biosynthesis*; D014660:Vasoactive Intestinal Peptide / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*
chemical_list: D012333:RNA, Messenger; D018005:Receptors, Vasoactive Intestinal Peptide; D051239:Receptors, Vasoactive Intestinal Peptide, Type II; D014660:Vasoactive Intestinal Peptide; D013739:Testosterone; D000242:Cyclic AMP